China NMPA Drug Inspection - Kangpu Pharmaceutical Co., Ltd. - Ginseng

The State Administration for Market Regulation issued Announcement No. 206 in December 2017, detailing significant findings regarding traditional Chinese medicine. Following extensive testing by the China National Institutes for Food and Drug Control, 39 batches of traditional Chinese medicine decoction pieces were identified as substandard. These unqualified products were produced by 34 enterprises, prominently including Jiangxi Bairen Traditional Chinese Medicine Decoction Pieces Co., Ltd., Beijing Bencao Fangyuan Pharmaceutical Co., Ltd., and Hebei Chufeng Traditional Chinese Medicine Pieces Co., Ltd. The primary violation involved the production and sale of these non-compliant medicinal items.

In response, provincial food and drug administration departments promptly implemented control measures, such as sealing and seizing the affected batches. The implicated companies were mandated to suspend sales and use, recall the substandard products, and undertake necessary rectifications. Operating under the regulatory framework of Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, the State Food and Drug Administration (SFDA) has instructed provincial authorities to conduct thorough investigations into these illegal activities. Investigation results must be publicized within three months, with timely reporting to the SFDA. A formal process is also established for enterprises to dispute product authenticity, triggering further verification by regulatory bodies.